IDH1 and neoplasm: In addition, FT2102 (Forma Therapeutics) and BAY1436032 (Bayer) also target IDH1 R132 tumors (R132X for BAY1436032), and occurring trials are selecting patients with various tumor forms, including GBM (NCT03684811 and NCT02746081).